Item 9 Labs Set To Transform Arizona Marijuana Market With New Line of Infused Pre-Rolls


Ryan Allway

September 13th, 2022

News, Top News


– Award-Winning Cannabis Product Brand Launches 1 Gram Concentrate Infused Pre-Rolls
– Item 9 Labs Ranked a Top 10 Brand in Arizona With Product in 60 Percent of State’s Dispensaries

 

PHOENIXSept. 13, 2022 /PRNewswire/ — Item 9 Labs, the premium, elevated mainstream cannabis product brand is adding a new permanent mainstay to its extensive product line-up. Following the success of its limited edition infused half-gram pre-rolls, the brand is launching 1 gram concentrate infused pre-rolls at participating dispensaries.

 

Item 9 Labs has been testing limited edition releases of seven half-gram infused pre-rolls in the Phoenix and Tucson markets as the trending industry category continues to maintain consistent triple digit growth throughout the state. The first limited-edition release in October 2021, Mummy Fingers, a crumble-infused pre-roll, sold out in 24 hours and inspired an entire line over the next year, including Badder Up!, Sugar Daze and the most recent Cosmic Crumble. Each release receiving rave reviews from retail partners and consumers alike.

 

“We are utilizing our wide range of concentrates to propel our intentionally grown flower into different experiences for our consumers and patients to enjoy by expanding their palate and introducing them to new synergistic terpene profiles,” said the brand’s Lab Director, Eric Eisele.

 

With increasing consumer demand and Item 9 Labs products sold in over 60 percent of Arizona dispensaries, Item 9 Labs is a top 10 brand in the market and one of the leaders in the category. The brand’s 1 gram infused pre-rolls are crafted with award-winning flower and live resin sugar, live resin badder or crumble concentrates which are grown and extracted in-house. Each infused pre-roll is individually packaged and made with ultra-thin, unrefined French paper to ensure a superior cannabis experience.

 

“Creating the perfect infused pre-roll product is an extensive, yet extremely rewarding process. We strive to stay ahead of the curve and feel inspired when refining our procedures,” said Chris Wolven, chief operating officer of Item 9 Labs. “The launch of our new permanent mainstay is a testament to the brand’s dedication for innovation and commitment to delivering masterfully-crafted cannabis products that our consumers can truly smell, taste and feel the difference.”

 

The Item 9 Labs infused pre-rolls offer a harmonious blend of intentionally grown flower and premium concentrates for a consistent cannabis experience in every draw. Through thorough research and development, the brand’s expert extraction and cultivation teams created a proprietary process that preserves the integrity of each infused pre-roll through even distribution of concentrate powder throughout award-winning flower.

 

“Our team works diligently to achieve the highest quality with a rigorous process to dissect our data for terpene profiles, flavor components and certain potencies. We are meticulous in matching the notes and tones of materials with proper formulations and temperatures for what we are striving to achieve at Item 9 Labs,” said the brand’s Vice President of Cultivation, Cory Carter. “We are always dedicated to excellence and are confident that we took our premium flower and turned it into something even more beautiful that stands with the highest product quality.”

 

For more information on Item 9 Labs and the brand’s wide range of premium cannabis products, visit item9labs.com. To find the new 1 gram concentrate infused pre-rolls at a local dispensary, visit Item 9 Labs’ Instagram @item_9_labs.

 

About Item 9 Labs

Item 9 Labs cultivates the highest quality cannabis products while providing transparency, consistency and well-being for an enhanced cannabis experience. With more than 20 podium finishes in Arizona marijuana competitions, Item 9 Labs is a trusted source for premium cannabis products. Starting with intentionally grown flower, the Item 9 Labs catalog spans premium products across five core categories, including several active cannabis strains, cannabis vape products, premium concentrates and Orion vape technology. Currently, Item 9 Labs is available at more than 60 percent of Arizona’s dispensaries. For additional information, visit item9labs.com.

 

Media Contact:
Lisa Sass
Serendipit Consulting
[email protected]
909-519-9171

SOURCE Item 9 Labs

 

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading